Company intelligence / Profile preview

Isomark

Madison, Wisconsin, United Statesisomark.com ↗

Ownership: Private
Development stage: Commercial

Overview

Isomark has developed and commercialized the Canary‑AG™ device for rapid, non-invasive screening of bacterial and viral infections in cattle. The system can detect at-risk animals up to two days before visible symptoms appear and delivers results within 30 seconds. The technology aims to reduce morbidity, mortality, medical costs, and unnecessary antibiotic use by enabling early intervention based on real-time data.

Therapeutic areas: Infectious Diseases
Modalities: Device (AI-based breath analysis)Non-pharmacological therapy (diagnostic/screening tool)
Industry: Veterinary

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Isomark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isomark.

Explore the full profile